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A rare variant in APOC3 is associated with plasma
triglyceride and VLDL levels in Europeans
Nicholas J. Timpson1, Klaudia Walter2, Josine L. Min1, Ioanna Tachmazidou2, Giovanni Malerba3,
So-Youn Shin1, Lu Chen2,4, Marta Futema5, Lorraine Southam2,6, Valentina Iotchkova2, Massimiliano Cocca2,
Jie Huang2, Yasin Memari2, Shane McCarthy2, Petr Danecek2, Dawn Muddyman2, Massimo Mangino7,
Cristina Menni7, John R.B. Perry8, Susan M. Ring9, Amadou Gaye10, George Dedoussis11, Aliki-Eleni Farmaki11,
Paul Burton10, Philippa J. Talmud5, Giovanni Gambaro12, Tim D. Spector7, George Davey Smith1, Richard Durbin2,
J. Brent Richards7,13, Steve E. Humphries5, Eleftheria Zeggini2, Nicole Soranzo2,4 & UK10K Consortium*
The analysis of rich catalogues of genetic variation from population-based sequencing
provides an opportunity to screen for functional effects. Here we report a rare variant in APOC3
(rs138326449-A, minor allele frequency B0.25% (UK)) associated with plasma triglyceride
(TG) levels ( 1.43 s.d. (s.e.¼0.27 per minor allele (P-value¼ 8.0 108)) discovered in
3,202 individuals with low read-depth, whole-genome sequence. We replicate this in 12,831
participants from ﬁve additional samples of Northern and Southern European origin ( 1.0
s.d. (s.e.¼0.173), P-value¼ 7.32 10 9). This is consistent with an effect between 0.5 and
1.5mmol l 1 dependent on population. We show that a single predicted splice donor variant
is responsible for association signals and is independent of known common variants. Ana-
lyses suggest an independent relationship between rs138326449 and high-density lipoprotein
(HDL) levels. This represents one of the ﬁrst examples of a rare, large effect variant identiﬁed
from whole-genome sequencing at a population scale.
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L
ipid levels are heritable risk factors for coronary artery
disease, and vascular outcomes and their therapeutic
manipulation has well-characterized impacts on disease
risk1. Genome-wide studies of common genetic variation and its
contribution to commonly measured lipid moieties have been
successful in identifying a large number of associated loci2,3;
however, the aggregate contribution of all of these conﬁrmed
common variants accounts currently for only about 10–12% of
the variation in low-density lipoprotein (LDL), high-density
lipoprotein (HDL) and triglycerides (TGs)3. With current
estimates of the heritability of these measures between 40% and
60%4, this leaves a considerable portion of variance unexplained.
This may be contributed to by smaller common variant effects,
as-yet undiscovered rare and potentially functional genetic
variation, gene-by-gene interaction (epistasis) or by
overestimates of heritability5. The availability of rich collections
of variants through whole-genome sequencing (WGS) of well-
phenotyped collections affords the unique opportunity to
discover novel and potentially functional genetic variation
associated with phenotypes of clinical interest.
Rare and highly penetrant variants identiﬁed in 24 different
human genes have been identiﬁed through sequencing studies in
families with rare monogenic lipid disorders6–8. Despite these
studies, however, there has been little examination of these
variants of low frequency (minor allele frequency (MAF)r5%)
on lipid proﬁle at the level of the population. Studies that focus
currently on exome content alone and have included variants of
intermediate and low frequency have, however, reported larger
genetic effects at lower MAF9–11. This type of work is relevant
given that variants of large effect sizes have been suggested to
segregate in populations at low frequencies under neutral or
purifying models of evolution12. These genes and variants are
likely to have considerable consequence on the health (expressed
as odds ratios on the cardiovascular risk) for those who carry
them, and may ultimately indicate novel therapeutic targets as
already shown for PCSK9 (ref. 13).
The UK10K Cohorts project (http://www.uk10k.org/studies/
cohorts.html) uses WGS to study the contribution of low-
frequency and rare variation on a broad range of complex
quantitative endpoints. Here we applied low read-depth WGS in
individuals from two deeply phenotyped British cohorts,
TwinsUK14 and the Avon Longitudinal Study of Parents and
Children (ALSPAC)15 to analyse TG levels. Analyses revealed
replicable evidence of a rare, functional, variant in the APOC3
gene (rs138326449-A, MAF B0.25% in the British population)
strongly associated with plasma TG levels. This represents one of
the ﬁrst examples of a rare, large effect variant identiﬁed from
WGS at a population based scale.
Results
Sequence data. A total of 3,910 individuals were sequenced to
average 6.7 mean read-depth using Illumina next-generation
sequencing technology (Supplementary Methods ‘(Low read-
depth WGS (cohorts data set)’). After applying stringent sample
quality control ﬁlters, a total of 3,621 unrelated individuals of
European ancestry (1,754 from TwinsUK and 1,867 from
ALSPAC) were available for association. TG measurements were
available for 3,202 individuals with sequence data, including 1,497
ALSPAC children (mean age 10 years, 50% females) and 1,705
TwinsUK adults, respectively (mean year 56 years, all females,
Supplementary Table 1).
Phenotypic association. To search the human genome for low-
frequency and rare variants associated with TG levels, we ﬁrst
tested associations with 13,074,236 single-nucleotide variants
(SNV) and 1,122,542 biallelic indels (MAF Z0.1%) called
from whole-genome-sequence data (Supplementary Table 2).
Associations of TGs with genetic variation were tested in the
ALSPAC and TwinsUK WGS data sets separately, and
study-speciﬁc summary statistics were combined using inverse
variance meta-analysis (Methods). There was no evidence
for inﬂation of summary statistics in the combined sample
(l(genomic control)¼ 0.99, Supplementary Fig. 1).
No variants gave evidence of association at conventional levels
of genome-wide signiﬁcance. However, four variants reached a
second more exploratory tier of evidence for discovery in tests of
association with TG (P-value r1 10 7) across the UK10K
sample and were of interest as they mapped to a region around
the APOC3 locus on chromosome 11. Two of the variants
found are common, rs964184-C (estimated allele frequency
(EAF)¼ 0.13%, P-value¼ 6.81 10 9) and rs66505542-T
(EAF¼ 0.14%, P¼ 1.87 10 8), in near-complete linkage dis-
equilibrium (r2¼ 0.90 in the UK10K sample) and have been
previously associated with TG levels2,3.
A third association meeting the nominal discovery threshold is
a novel variant with low MAF, also mapping to the APOC3 locus
(Fig. 1). The rs138326449-A allele has an MAF of 0.25% and was
associated with decreased TG levels corresponding to 1.43
(s.e¼ 0.27) s.d. per allele (P-value¼ 8.02 10 8) in the
combined sample of 3,202 TwinsUK and ALSPAC participants
with whole-genome sequence data (Fig. 2 and Table 1).
Signal validation and reﬁnement. We ﬁrst validated whole-
genome sequence-derived rs138326449 genotypes using over-
lapping genotype calls and showed perfect concordance in both
TwinsUK and ALSPAC (Methods). We then took forward the
variant for replication in ﬁve additional cohorts (N¼ 12,831;
Supplementary Table 1), where the variant was imputed with
high accuracy (deﬁned by imputation info values Z0.4) using a
novel reference panel obtained from combining UK10K data with
data from the 1000 Genomes Project (Supplementary Methods).
The rs138326449-A allele had similar allele frequency in the ﬁve
additional cohorts, with the highest value observed in a popula-
tion isolate from Greece (MAF¼ 0.8%; Supplementary Table 1).
The ﬁve cohorts provided independent replication of the
association with decreased TG ( 1.0 (s.e.¼ 0.173) s.d.,
P-value¼ 7.32 10 9, combined discovery and replication
P-value¼ 6.92 10 15), suggesting that this variant contributes
to decreasing TG levels in multiple populations of Northern and
Southern European origin, with similar effect sizes and allelic
frequency.
We further tested association of the splice variant with the
other three main lipid sub-fractions HDL, LDL and total
cholesterol (TC), and with very-low-density lipoprotein (VLDL).
The A allele at rs138326449 was associated with decreased VLDL
levels in a combined sample of 7,891 participants with available
data ( 1.312 (s.e.¼ 0.199), P-value¼ 4.16 10 11) and with a
moderate increase in HDL in 16,062 study participants (0.624
(s.e.¼ 0.143), P-value¼ 1.36 10 5; Table 1 and Fig. 2). Asso-
ciations with LDL and TC were negligible (Supplementary
Table 3 and Supplementary Fig. 2).
Analysis of the residual association between rs138326449 and
TG levels conditional on other lipid-sub-fractions showed
expected patterns in both children and adults when taking into
account lipid-lowering drugs. Adjustment for VLDL removed the
association between rs138326449 and TG levels. In the children of
the ALSPAC study, there was also evidence of association
between rs138326449 and HDL levels after adjustment for either
TG or VLDL, which was also seen (although less strongly) in the
1958 British Cohort (Table 2).
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Further analysis of rare genetic variation. We next analysed the
joint ALSPAC and TwinsUK sample with whole-genome
sequence data to explore the contribution of common and rare
genetic variants to TG associations in the APOC3 region. We
focused on a 640-kb recombination window containing the novel
signal at rs138326449. Association between rs138326449 and TG
was assessed conditioning simultaneously on known associated
variants best tagging all previously published common variant
signals at this locus (rs964184 and rs2075290 (refs 2,3)) and other
potentially novel independent loci derived from region-speciﬁc
conditional analysis in the UK10K data. Other than rs138326449
and positive controls from previous studies, the only other
potential independent signal single-nucleotide polymorphism
(SNP) in this region was rs193204541, and neither did
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Figure 2 | Association of lipid levels with rs138326449 at APOC3. Boxplots of associations between rs138326449 and TG, VLDL and HDL levels
are shown as a function of carriage of allele A. Plots for HDL and TC are shown in Supplementary Fig. 2. P values indicate evidence for a linear
relationship between lipid sub-fraction level and genotype (assuming an additive model). Box edges indicate the interquartile range (IQR; central line
indicating the 50th centile) with the whisker indicating the lowest and highest daya still within 1.5 IQR of respective quartiles.
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Figure 1 | Regional plot of association between genetic variation at the APOC3 locus and plasma TG levels. The ﬁgure is drawn using the UK10K
Dalliance Browser. The tracks reported in a indicate (top to bottom): (i) P-value (on the –log10 scale) for association of SNPs in the APOC3 region with TG
levels. Symbols are coloured corresponding to r2 to indicate the extent of linkage disequilibrium of each SNP in the region with the index SNPs rs964184
(red square) and the splice variant rs138326449 (blue triangle) marked; (ii) GENCODE genes (from ftp://ngs.sanger.ac.uk/production/gencode/). (b) A
cartoon illustrating the genic location of rs138326449 in the context of variable splicing of the APOC3 gene.
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conditional analysis, including this variant, abolish evidence for
association at rs138326449 (Supplementary Table 4) nor was this
particular signal supported using available replication data.
We also examined the potential additional contribution of
variants (frequency at or below 1%) by using Sequence Kernel
Association Testing (SKAT16) in B3-kb windows tiled over the
APOC3 region (Methods). Overall, seven windows had evidence
for association with TG (P-valueo1 10 3, equivalent to
P-value¼ 0.05 given a Bonferroni correction for multiple testing).
The strongest of these was at chr11:116698501–116701500
(P-value¼ 7.6 10 7). Despite speciﬁcally testing aggregates of
rare variation, either one or a combination of the three
independent SNP/SNV variants described above (that is,
rs964184, rs2075290 and rs138326449) could account for six
out of seven SKAT signals in this region (Supplementary Fig. 3).
One region (chr11:116769001–116772000) showed nominal
evidence of association with plasma TG levels (P-value¼
4 10 4) that could not be accounted for by association of
any given individual SNV and that may represent a novel signal
driven by multiple rare variants. Regional plots for all major lipid
sub-fractions and SKAT results for this region can be found in
Supplementary Figs 4 and 5). Results from a gene-based SKAT
analysis across the APOC3 gave greatest evidence for association
with APOC3 speciﬁcally; however, this region neither yielded
results stronger than that shown from non-genic tiling nor were
further regions implicated (Supplementary Table 5).
Variance explained. Overall, in UK10K data across ALSPAC and
TwinsUK, genetic variation in the APOC3 region accounted for
2.71% (s.e.¼ 1.39) of phenotypic variance in TG. This is in
contrast to estimates of variance explained from the analysis of
rs138326449 alone in children and adults not in the original
discovery collections, which varied from 0.27 to 0.39%
(Supplementary Table 6). Association results for known,
TG-speciﬁc, positive controls are reported in Supplementary
Table 7.
Discussion
Within the cohorts arm of the UK10K study, we have collected
low read-depth, whole genome sequence data and used this with a
validation and replication panel to describe a rare SNV (MAF
B0.2% in Europeans) strongly associated with plasma TG. The
variant rs138326449 accounts for single point and sequence
kernel-based association signals at the known Mendelian locus
APOC3, independently of known associations at this locus. We
have replicated the association in up to 12,852 study participants
from 5 additional population samples of Northern and Southern
European origin, conﬁrming this association, albeit at a more
modest level (difference in plasma TG levels  1.0 s.d.
(s.e.¼ 0.173) per minor allele). The rare allele association with
plasma TG level is consistent with an effect of between 0.5 and
Table 1 | Summary of genetic associations between
rs138326449 and levels of TG, VLDL and HDL in discovery
and replication sample sets.
Sample Metric TG HDL
TwinsUK WGS Beta (s.e.) 0.60 (0.23) 0.328 (0.18)
(EAF 0.23%) P-value 7.7 10 3 0.06
N 1,705 1,713
Info metric 0.78 0.78
ALSPAC WGS Beta (s.e.) 0.52 (0.20) 0.33 (0.11)
(EAF 0.28%) P-value 9.3 10 3 3.4 10 3
N 1,497 1,497
Info metric 0.94 0.94
Discovery combined Beta (s.e.)  1.43 (0.27) 0.84 (0.27)
P-value 8.0 10 8 2.1 10 3
N 3,202 3,210
1958BC (EAF 0.15%) Beta (s.e.)  1.35 (0.33) 1.04 (0.32)
P-value 4.3 10 5 1.2 10 3
N 5,485 5,493
Info metric 0.55 0.55
INCIPE (EAF 0.26%) Beta (s.e.) 0.93 (0.43) 0.63 (0.42)
P-value 0.03 0.13
N 1,382 1,382
Info metric 0.78 0.78
TwinsUK GWAS Beta (s.e.) 0.90 (0.36) 0.79 (0.34)
(EAF 0.29%) P-value 0.01 0.02
N 1,882 1,896
Info metric 0.75 0.75
ALSPAC GWAS Beta (s.e.)  1.83 (0.56) 1.30 (0.55)
(EAF 0.2%) P-value 1.2 10 3 0.02
N 2,820 2,820
Info metric 0.77 0.77
HELIC M (EAF 0.78%) Beta (s.e.)  1.26 (0.36) 0.74 (0.36)
P-value 5.4 104 0.04
N 1262 1264
Info metric 0.42 0.42
Combined replication Beta (s.e.)  1.00 (0.17) 0.54 (0.17)
P-value 7.3 109 1.3 10 3
N 12,831 12,855
Overall Beta (s.e.)  1.13 (0.15) 0.62 (0.14)
P-value 6.9 10 15 1.4 10 5
N 16,033 16,065
ALSPAC, Avon Longitudinal Study of Parents and Children; EAF, estimated allele frequency;
GWAS, genome-wide association study; HDL, high-density lipoprotein; TG, triglyceride; VLDL,
very low-density lipoprotein.
Data is reported for the discovery sample of TwinsUK and ALSPAC whole-genome sequence,
and for the ﬁve replication samples where the variant was imputed. For each trait, the Beta (s.e.)
is expressed in s.d. units for the population distribution of the corresponding trait. Beta reports a
standardized per allele effect and Info metric reports the ‘proper info’ from the imputation
process.
Table 2 | Conditional associations between rs138326449
and lipid sub-fraction in the ALSAPC and the 1958BC.
TGy LDLy HDLy VLDLy
(A) ALSPAC
TGc – 0.088 0.575 0.001
LDLc –1.362 – 1.100 –1.361
HDLc –0.840 0.070 – –0.839
VLDLc –0.001 0.088 0.575 –
(B) 1958BC
TGc – 0.088 0.238 0.025
LDLc –0.669 – 0.515 –0.627
HDLc –0.454 0.017 – –0.413
VLDLc –0.046 0.100 0.251 –
(C) Correlation
TG – 0.042 –0.4461 1.000
LDL 0.181 – 0.041 0.0419
HDL –0.475 –0.053 – –0.446
VLDL 0.986 0.170 –0.477 –
1958BC, 1958 Birth Cohort; ALSPAC, Avon Longitudinal Study of Parents and Children; HDL,
high-density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride; VLDL, very low-density
lipoprotein.
Sections A and B show b-coefﬁcients from linear regression of a dependent variable lipid sub-
fraction (y) on rs138326449 conditioning on each of the other lipid sub-fractions(C) in ALSPAC
and the 1958BC, respectively. Pink shading indicates P-values for association with rs138326449
Po0.0001 and green Po0.05. Emboldened and italic entries highlight the residual relationship
between rs138326449 and HDL cholesterol. Models include age, age54, sex alongside the
conditioned lipid along with lipid-lowering drug status for the 1958BC. Section C shows
Pearson’s correlation coefﬁcient between lipid sub-fractions in ALSPAC (above diagonal) and
1958BC (below diagonal).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms5871
4 NATURE COMMUNICATIONS | 5:4871 | DOI: 10.1038/ncomms5871 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
1.5mmol l 1 across children and adults dependent on popula-
tion (Supplementary Fig. 6a). This is considerably larger than that
reported in recent examinations of common variation and is one
of the ﬁrst of this nature to be reported from the use of
population-based WGS. In context, the largest reported lipid
effects from existing genome-wide association study (GWAS) are
up to ﬁve times greater than that for the commonly recognized
FTOrs9939609 variant and adult body mass index (which is
B0.01 s.d. change in body mass index); however, these are still
more than 20 times lower than that seen here2,17. It is also notable
that this effect is found in both children and adults, and in the
presence or absence of lipid-altering interventions (Supplemen-
tary Fig. 6b).
The human APOC3 gene is located in a gene cluster together
with the APOA1 and APOA4 genes on the long arm of
chromosome 11 (ref. 18). APOC3 is expressed in the liver and
intestine, and is controlled by positive and negative regulatory
elements that are spread throughout the gene cluster19–21. There
is considerable evidence to support the genetic contribution of
this locus to hyperlipidaemia and, in particular, there have been
correlations between apoCIII levels, plasma TG and VLDL
TGs22,23. With this, the use of ﬁbrates as a therapeutic
intervention (known to reduce the apoCIII synthesis rate in
humans23) has suggested that there is an important role for
APOC3 in TG metabolism. Moreover, transgenic mice expressing
human apoCIII have shown that expression in the liver and
intestine is correlated with elevated levels of VLDL TG, and
where apoE is knocked out and APOC3 expressed, huge
accumulations of TG-rich VLDL can occur24,25.
The splice donor site reported here lies in a region of
chromosome 11 previously shown to contain both common and
rare variants affecting plasma TG levels. Restriction fragment
length polymorphism variation within the non-coding part of
exon 4 at this locus, haplotypic characterization of variation in the
region and a single change within exon 3 of APOC3 have all been
related to either hypertriglyceridemia or familial combined
hypercholesterolaemia26–28. More recently, a functional variant
site (R19X) adjacent to rs138326449 and resulting in APOC3 loss-
of-function in homozygote carriers has been reported
independently in two genetic isolates from the United States
and Greece; however, this variant is very rare (EAF¼ 0.05%) in
the general European population and does not contribute to
variance in TG in this study29,30. In each case, the impaired
expression of APOC3 is associated with reduced plasma TG levels
and a coincident increase in HDL, in agreement with the
inhibiting action of apoCIII on lipoprotein lipase. In the data here
from UK10K, the total variance in plasma TGs explained by all
genetic variation at this locus (down to and below 1% MAF) is
B2.7%. This is in comparison with this novel, low-frequency,
genetic variant that accounts for somewhere between 0.27% and
0.39% of phenotypic variance.
The rs138326449 variant affects the essential di-nucleotide
50-splicing site (GT to AT) of the ﬁrst protein-coding exon of the
protein-coding gene APOC3. The rare, TG-decreasing A allele is
predicted to disrupt the correct splicing of the ﬁrst protein-coding
exon of APOC3 (containing the Apo-CIII domain (PF05778) and
a signal peptide (1–20 aa)), resulting in a marked change of the
50-splicing site score (from 4.37 (G) to  3.81 (A))31
(Supplementary Fig. 7). Although it was not possible to validate
the splicing event using existing liver expression atlas generated
by the GTex project32 because of the lack of carriers in
this data set, we note that this position is highly conserved
(phastCons¼ 0.996, a measurement of evolutionary conservation
based on multiple alignments of 100 vertebrates) through
vertebrates33, supporting a probably potential, functional
consequence for this site.
Recognized within the Adult Treatment Panel III and as part of
the deﬁnition of the metabolic syndrome (https://www.nhlbi.-
nih.gov/health-pro/guidelines/current/cholesterol-guidelines/
index.htm), TG and TG-rich remnants are probably risk factors
in cardiovascular disease34. Meta-analysis of 17 prospective
studies has suggested that TGs are independent contributors to
coronary heart disease risk and data from both the Mu¨nster Heart
and Caerphilly studies have supported this35,36. This effect
appears to be present independent of LDL-cholesterol and HDL-
cholesterol levels37,38; however, these ﬁndings are not simple in
interpretation. The current largest meta-analysis based on the
same phenotypes has shown contradictory results39 and, in
addition, an outstanding issue in these analyses remains the
difﬁculty in assessing the independent impact of reduced or
elevated TG levels from HDL. In our data, rs138326449 is
associated with reduced TG in line with predicted lower levels of
functional apoCIII in carriers of the A allele. However, this effect
is not unique to TG levels, with a coincident and independent
association with HDL making the interpretation of downstream
effects of this variant (or variants at this locus exerting a similar
effect) difﬁcult in terms of causal inference.
In the absence of a clear explanation for the complex
relationship between apolipoprotein gene effects and multiple
lipid outcomes, the notion of overall lipid proﬁle as a risk factor
may be the most acceptable paradigm. To this end, variants such
as rs138326449 do potentially provide information about the
impact of interventions aimed at changing lipid proﬁle. In this
context, the impact of APOC3 inhibition through approaches
such as targeted antisense oligonucleotide use40 can be modelled
given observations such as that made in this study. This
essentially represents an applied Mendelian randomization41
experiment, and with coincident disease status available, this
type of study may help identify future, gene-targeted, therapeutic
interventions.
Methods
ALSPAC WGS discovery sample. The ALSPAC is a long-term health research
project. More than 14,000 mothers enrolled during pregnancy in 1991 and 1992,
and the health and development of their children has been followed in great detail
ever since. A random sample of 2,040 study participants was selected for WGS. The
ALSPAC Executive Committee approved the study and all participants gave signed
consent to the study.
Non-fasting plasma levels of TC, HDL and TG at age 9 years were measured
with enzymatic colorimetric assays (Roche) on a Hitachi Modular P Analyser.
HDL, TGs and TC (all in mmol l 1) were measured as described previously42. LDL
was derived from the Friedwald formula: TC-(HDL Cholesterolþ (TG/2.19))43. We
calculated VLDL as VLDL Cholesterol (mmol l 1)¼TC-LDL Cholesterol–HDL
Cholesterol.
TwinsUKWGS discovery sample. TwinsUK is a nation-wide registry of volunteer
twins in the United Kingdom, with about 12,000 registered twins (83% female,
equal number of monozygotic and dizygotic twins, predominantly middle-aged
and older). Over the last 20 years, questionnaire and blood/urine/tissue samples
have been collected for over 7,000 subjects, as well as three comprehensive
phenotyping assessments. The primary focus of study has been the genetic basis of
healthy aging process and complex diseases, including cardiovascular, metabolic,
musculoskeletal and ophthalmologic disorders. Alongside the detailed clinical,
biochemical, behavioural and socio-economic characterization of the study
population, the major strength of TwinsUK is availability of several ‘omics’
technologies for the participants. The database was used to study the genetic
and environmental aetiology of age-related complex traits and diseases. The
St Thomas’s Hospital Ethics Committee approved the study and all participants
gave signed consent to the study.
Enzymatic colorimetric assays were used to measure serum levels of TC, HDL
and TGs, and were measured using three analysing devices (Cobas Fara; Roche
Diagnostics, Lewes, UK; Kodak Ektachem dry chemistry analysers (Johnson and
Johnson Vitros Ektachem machine, Beckman LX20 analysers, Roche P800 modular
system)). The majority of discovery samples were fasted before measurement
(96%).
Low read-depth WGS (cohorts data set). Low read-depth WGS was performed at
both the Wellcome Trust Sanger Institute and the Beijing Genomics Institute
(BGI). DNA (1–3 mg) was sheared to 100–1,000 bp using a Covaris E210 or LE220
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(Covaris, Woburn, MA, USA). Sheared DNA was subjected to Illumina paired-end
DNA library preparation. Following size selection (300–500 bp insert size), DNA
libraries were sequenced using the Illumina HiSeq platform as paired-end 100 base
reads according to the manufacturer’s protocol.
Alignment and BAM processing. Data generated at the Sanger Institute and BGI
were aligned to the human reference separately by the respective centres. The BAM
ﬁles produced from these alignments were submitted to the European Genome-
phenome Archive. The Vertebrate Resequencing Group at the Sanger Institute then
performed further processing.
Alignment. Sequencing reads that failed quality control (QC) were removed using
the Illumina GA Pipeline, and the rest were aligned to the GRCh37 human
reference, speciﬁcally the reference used in Phase 1 of the 1000 Genomes
Project (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/reference/
human_g1k_v37.fasta.gz). Reads were aligned using BWA (v0.5.9-r16)44.
BAM improvement and sample ﬁle production. Further processing to improve
SNV and INDEL calling, including realignment around known INDELs, base
quality score recalibration, addition of BAQ tags, merging and duplicate marking
follows that used for Illumina low-coverage data in Phase 1 of the 1000 Genomes
Project. Software versions used for UK10K for the steps described in that section
were GATK version 1.1-5-g6f43284, Picard version 1.64 and samtools version
0.1.16.
Variant calling. SNV and INDEL calls were made using samtools/bcftools (version
0.1.18-r579)45 by pooling the alignments from 3,910 individual low read-depth
BAM ﬁles. All-samples and all-sites genotype likelihood ﬁles (bcf) were created
with samtools mpileup.
INDEL pre-ﬁltering. The observation of spikes in the insertion/deletion ratio in
sequencing cycles of a subset of the sequencing runs were linked to the appearance
of bubbles in the ﬂow cell during sequencing. To counteract this, the bamcheck
utility from the samtools package was used to create a distribution of INDELs
per sequencing cycle. Lanes with INDELs predominantly clustered at certain read
cycles were marked as problematic (159 samples). In the next step, we checked
mapped positions of the affected reads to see whether they overlapped with called
INDELs, which they did for 1,694,630 called sites. The genotypes and genotype
likelihoods of affected samples were then set to the reference genotype unless there
was a support for the INDEL also in a different, unaffected lane from the same
sample. In total, 140,163 genotypes were set back to reference and 135,647 sites
were excluded by this procedure. Note that this step was carried out on raw,
unﬁltered calls before Variant Quality Score Recalibration ﬁltering.
Site ﬁltering. Variant Quality Score Recalibration46 was used to ﬁlter sites. For
SNVs, the GATK (version 1.3–21) UniﬁedGenotyper was used to recall the sites/
alleles discovered by samtools to generate annotations to be used for recalibration.
Recalibration for the INDELs used annotations derived from the built-in samtools
annotations. The GATK VariantRecalibrator was then used to model the variants,
followed by GATK ApplyRecalibration, which assigns VQSLOD (variant quality
score log odds ratio) values to the variants. For SNV sites, a truth (GRCh37)
sensitivity of 99.5%, which corresponded to a minimum VQSLOD score of
 0.6804 was selected; that is, for this threshold, 99.5% of truth sites were retained.
For INDEL sites, a truth sensitivity of 97%, which corresponded to a minimum
VQSLOD score of 0.5939 was chosen. Finally, we also introduced the ﬁlter
Po10 6 to remove sites that failed the Hardy–Weinberg equilibrium (302,388
sites removed) and removed sites with evidence for differential frequency (logistic
regression P-value41e 2) between samples sequenced at BGI and Wellcome
Trust Sanger Institute (277,563 sites removed).
Given the presence of structure by genotyping batch, we ran a genome-wide
association analysis for the binary variable ‘sequencing centre’ (‘BGI’/‘SANGER’)
using a logistic regression model. SNPs (335,982) were associated with batch at a
conservative threshold of P-valuer0.01 and formed a list that were subsequently
ﬁltered out from the genotype set, removing the batch effect due to sequencing
centre.
Post-genotyping sample QC. Of the 4,030 samples (1,990 TwinsUK and 2,040
ALSPAC) that were submitted for sequencing, 3,910 samples (1,934 TwinsUK and
1,976 ALSPAC) were sequenced and went through the variant calling procedure.
Low-quality samples were identiﬁed before the genotype reﬁnement by comparing
the samples with their GWAS genotypes using B20,000 sites on chromosome 20
(see Supplementary Methods for full details).
Genotype reﬁnement. The missing and low-conﬁdence genotypes in the ﬁltered
VCFs were reﬁned out through an imputation procedure with BEAGLE 4, rev909
(ref. 47). The programme was run with default parameters (see Supplementary
Methods for full details). After imputation, chunks were recombined using the
vcf-phased-join script from the vcftools [vcftools] package.
Post-reﬁnement sample QC. Additional sample-level QC steps were carried
out on reﬁned genotypes, leading to the exclusion of additional 17 samples
(16 TwinsUK and 1 ALSPAC) because of one or more of the following causes:
(i) non-reference discordance with GWAS SNV data45% (12 TwinsUK and 1
ALSPAC), (ii) multiple relations to other samples (13 TwinsUK and 1 ALSPAC) or
(iii) failed sex check (3 TwinsUK and 0 ALSPAC).
To exclude the presence of participants of non-European ancestry in our data
set, we merged a pruned data set to the 11 HapMap3 populations48 and performed
a principal components analysis using EIGENSTRAT49. A total of 44 participants
(12 TwinsUK and 32 ALSPAC) did not cluster to the European (CEU) cluster of
samples and were removed from association analyses.
The ﬁnal sequence data set that was used for the association analyses comprises
3,621 samples (1,754 TwinsUK and 1,867 ALSPAC).
Re-phasing. SHAPEIT2 (ref. 50) was then used to rephase the genotype data. The
VCF ﬁles were converted to binary ped format. Multiallelic and MAFo0.02%
(singleton and monomorphic) sites were removed. Files were then split into 3-mbp
chunks with ±250 kbp ﬂanking regions. SHAPEIT (v2.r727) was used to rephase
the haplotypes.
Imputation from the combined UK10Kþ 1000 Genomes Panel. For each of the
cohorts, we had additional GWA data available. For ALSPAC, 6,557 samples were
measured on Illumina HumanHap550 arrays and passed QC (population stratiﬁ-
cation, sex check, heterozygosity and relatedness (identity by state (IBS)40.125)).
For TwinsUK, 2,575 samples were genotyped on Illumina HumanHap300 or
Illumina Human610 arrays. These samples passed QC on relatedness (IBS40.125),
population stratiﬁcation, heterozygosity, zygosity and sex checks. Samples from the
imputed data sets were unrelated to the sequence data sets (IBS40.125). Variants
discovered through WGS of the TwinsUK and ALSPAC cohorts were used for the
development and use of a reference panel for imputation within the TwinsUK and
ALSPAC GWA data sets. In other collections, these along with variants known
from 1000 Genomes were imputed increasing the sample size for single point
association analysis to 12,724 subjects. We developed new functionality in
IMPUTE2 (ref. 51) that uses each reference panel to impute the missing variants in
its counterpart, and then combine the two reference panels at the union set of sites.
We tested the 3 reference panels for imputing 3 SNP array data, a sub-sample of
1,000 individuals from the UK10K WGS data set, 4 European samples (3 CEU, 1
TSI) sequenced by Complete Genomics (depth: 80 )52 and an Italian isolate
genotyped on core-exome SNP array (see Supplementary Methods for full details).
Validation genotyping. For ALSPAC, the entire cohort (10,145 participants,
including 38 carriers of the rare A allele) was genotyped using KASP at KBioscience
(www.lgcgenomics.com/; see Supplementary Methods for full details). For
TwinsUK, genotyping accuracy was evaluated against a data set comprising
B250 high-coverage exomes sequenced in overlapping samples53. Of the six
carriers detected in our study, four were overlapping and correctly called also in the
exome data set, yielding a genotyping accuracy of 100%. There was 100%
concordance with the genotypes called from the whole-genome data set.
Trait standardization. Each cohort applied a standardized protocol for prepara-
tion of phenotypes, as follows. Female and male participants were divided into
separate groups and TwinsUK participants were further divided into two unrelated
subsets. Outliers deviating Z4 or 5 s.d. (depending on the study) from the sample
mean for a given trait were excluded from analysis (for this step, TGs were log
transformed). The ﬁltering of TG data by extremes of phenotype does not have a
substantive impact on the numbers of rare variant carriers in this data set (although
overall there is likely to be an enrichment for rare variant carriage in at the low end
of the TG distribution in large collections). To approximate normality, each data
set was inverse normal rank transformed in each group separately, and residuals
were further computed by adjustment for age and age squared as a ﬁxed effect. In
TwinsUK, analyser effects were computed additionally as a random effect if
associated with phenotype. Finally, residuals were standardized before combining
males and females. In ALSPAC, trait residuals were computed jointly from the
WGS and GWA samples. Details of trait transformation and statistical methods
applied in each study are summarized in Supplementary Table 2. For conditional
lipid analyses (Supplementary Table 4), all lipid sub-fractions and TC were inverse
rank transformed before analyses. Pearson’s correlation coefﬁcients were used to
assess the correlation between variables, and linear regression was used to assess
the relationship between variation at rs138326449 and lipid sub-fraction having
serially conditioned on other lipids. For main analyses, where VLDL was missing
from replication collections, it was not included given the correlation between TG
and VLDL when derived from TC, HDL and LDL. This is illustrated where for
regional analyses across ALSPAC and the 1958 British Cohort VLDL is calculated
for purposes of illustration (Table 2).
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Associations between lipids and SNVs and indels. We assessed associations
between 14,196,778 genetic variants (13,074,236 SNPs and 1,122,542 biallelic
indels, MAFZ0.1%) and lipid traits (LDL, HDL, TG, TC and VLDL) calculated as
described before, using linear regression models assuming additive genetic models.
For primary analyses, associations were tested using a genotype dosage-based test
implemented in the SNPTESTv4.2 software package54, apart for the TwinsUK
GWAS and HELIC MANOLIS data sets, where mixed linear models were used to
account for family structure using the GEMMA software55.
Meta-analysis of associations with SNVs. Summary statistics from individual
studies were combined using ﬁxed-effect inverse variance meta-analysis
implemented in GWAMA v2.1 (ref. 56).
Region-speciﬁc analyses. Conditional analyses of genotype and rare variant
aggregate association were undertaken within a joint sample from the UK10K
cohort WGS data set (ALSPAC and TwinsUK) adjusting for study origin by
residualizing transformed TG on an indicator variable for study. Records of region-
speciﬁc recombination used to derive the recombination interval boundaries were
retrieved from (http://hapmap.ncbi.nlm.nih.gov/downloads/recombination/2011-
01_phaseII_B37/), and this analysis was limited to a 640-kb window of chromo-
some 11 marked by a recombination fractiono25%. Evidence for previous genetic
associations was available from existing studies2,3 and best tag variants for positive
controls were derived by using PLINK to assess linkage disequilibrium across
positive controls57. Evidence for further novel independent TG associations across
the APOC3 region in this data set were assessed using GCTA58. We considered all
SNPs and bi-allelic indels seen at least twice that had any evidence of association
with TG (Po1 10 3) alongside those previously associated with lipid levels
irrespective of association result in this sample59–60. Conditional analyses were
undertaken for rs138326449 given all potentially independent contributing loci in
this region using GCTA. GCTA was also used to calculate the total genetic
contribution to variance in TG for the same region having calculated a matric of
relatedness from the whole of chromosome 11. In addition to regional analyses,
estimates of variance explained for rs138326449 alone were derived from the
ALSPAC and 1958 birth cohort collections using linear regression taking into
account the covariables age, age, sex and lipid-lowering drugs in the case of the 1958
birth cohort. Analyses for this were undertaken using STATA version 13 (StataCorp.
2013. Stata Statistical Software: Release 13; StataCorp LP, College Station, TX).
SKAT16 was undertaken across the APOC3 region. Sequence-derived genotypes
with MAF capped at 1% were extracted and split into sub-regions containing as
close to 50 variants as possible. These were analysed using SKAT and all signals
with evidence for association P-valueo1 10 3, equivalent to P-value¼ 0.05
given a Bonferroni correction for multiple testing across this region, were taken
forward for further analyses. We then re-formulated phenotype-containing fam
ﬁles for SKAT analysis having conditioned sequentially on known positive control
or novel independent contributing SNPs in the region before re-running SKAT
analyses. Results from a gene-based SKAT analysis were generated by running
SKAT (again with MAF r1%) for genes contained within the APOC3 region.
Genes for this analysis were deﬁned by GENCODE (v15) within positions
115,820,914 and 117,103,241 on chromosome 11. In more detail, variants within
exons and splice variants were tested in windows up to 51 variants per window. If
there were450 exonic and splice variants per gene, then variants were split in two
ways: ﬁrst by combining neighbouring exons so that the number of variants was
about evenly split between windows, and second by tiling across the concatenated
exons with maximal 51 variants per window but starting halfway the ﬁrst window
that was generated by the ﬁrst approach.
Replication samples. Description of the replication samples is given in the
Supplementary Methods.
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Erratum: A rare variant in APOC3 is associated with
plasma triglyceride and VLDL levels in Europeans
Nicholas J. Timpson, Klaudia Walter, Josine L. Min, Ioanna Tachmazidou, Giovanni Malerba, So-Youn Shin,
Lu Chen, Marta Futema, Lorraine Southam, Valentina Iotchkova, Massimiliano Cocca, Jie Huang, Yasin Memari,
Shane McCarthy, Petr Danecek, Dawn Muddyman, Massimo Mangino, Cristina Menni, John R.B. Perry,
Susan M. Ring, Amadou Gaye, George Dedoussis, Aliki-Eleni Farmaki, Paul Burton, Philippa J. Talmud,
Giovanni Gambaro, Tim D. Spector, George Davey Smith, Richard Durbin, J. Brent Richards, Steve E. Humphries,
Eleftheria Zeggini, Nicole Soranzo & UK10K Consortium
Nature Communications 5:4871 doi: 10.1038/ncomms5871 (2015); Published 16 Sep 2014; Updated 12 May 2015
During the production of this Article, errors were introduced in the frequencies of the variants rs964184-C and rs66505542-T reported
in the Results section. The correct frequencies are 13 and 14%, respectively.
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